Spark Therapeutics’ One-time Gene Therapy LUXTURNA Gets EU Approval
Spark Therapeutics (ONCE), a commercial gene therapy company, announced Friday that the European Commission has granted marketing authorization for LUXTURNA (voretigene neparvovec).
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for...
DUBLIN, March 11, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Ne
Lilly makes $8 billion bet on drugs for rare cancers with...
Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy
Sandoz drives differentiated portfolio with deal to commercialize new treatment for...
(GLOBE NEWSWIRE via COMTEX) -- Novartis International AG / Sandoz drives differentiated portfolio with deal to commercialize new treatment fo
MacroGenics Announces Positive Results from Pivotal Phase 3 SOPHIA Study of...
Source: globenewswire.com
MacroGenics Inc. has announced positive results from SOPHIA, a Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients. Margetuximab is...
FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with...
ROCKLAND, Mass. and NEW YORK, May 14, 2019 /PRNewswire/ -- BAVENCIO is the first anti-PD-L1 in combination with INLYTA approved by FDA for first-line treatmen
